Categories: News

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of November 30, 2022

Disclosure of Share Capital and Voting Rights Outstanding
as of November 30, 2022

(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Charenton-le-Pont, France (December 22, 2022 – 6:00 pm) – As of November 30, 2022, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks down as indicated below.

  November 30, 2022
Shares outstanding           447,452,7641
Number of real voting rights (excluding treasury shares) 444,659,008
Theoretical number of voting rights (including treasury shares) 447,452,764

It is to be noted that voting rights are capped at 31%, applicable to any shareholder, in accordance with a formula contained in article 23 of EssilorLuxottica’s by-laws2.

For further information, please consult the Prospectus which received Visa No. 18-460 from the AMF on September 28, 2018 and its Securities Note Supplement which received Visa No. 18-494 from the AMF on October 23, 2018, available on the website www.essilorluxottica.com.

1Including 38,302 shares delivered but not yet registered as of November 30, 2022.
2EssilorLuxottica’s by-laws are available on the Company’s website under the section Governance / Publications.

Attachment

Staff

Recent Posts

The Power of Tracking: New Preliminary Data Underscores How MyFitnessPal Supports Weight Management Goals

Research highlights how nutrition tracking drives success for weight loss and health goals NEW YORK,…

2 hours ago

Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide

Richland, WA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to…

5 hours ago

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing…

5 hours ago

Optinose Announces 1-for-15 Reverse Stock Split

YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company…

5 hours ago